Stocks · Healthcare · Biotechnology
Arvinas, Inc. ARVN
$7.46 +0.67% Close, Oct 5, 2026 · NASDAQ · Market cap $478.1M
Weak trend
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -4.5% from -31.8% a year earlier.
- The diluted share count fell 10.0% in a year, mainly through buybacks.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
Growth74Positive
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 17%
- Revenue growth, 3-year CAGRTop 25%
- Revenue growth accelerationTop 5%
Quality61Neutral
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 35%
- Gross marginTop 12%
- Operating marginTop 47%
- Cash conversion (OCF / net income)Bottom 1%
- Accruals (lower is better)Bottom 3%
- Net debt / EBITDA (lower is better)Top 2%
Value65Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 24%
- Free-cash-flow yieldBottom 10%
- EBITDA / enterprise valueTop 36%
- Sales / enterprise valueTop 14%
Momentum17Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 37%
- 6-month returnBottom 13%
- 1-year return vs S&P 500Bottom 29%
- Distance from 52-week highBottom 30%
- Trend checklist (0–4)Bottom 13%
Revisions87Strong
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 43%
- Upside to consensus price targetTop 39%
Stability60Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 35%
- Maximum drawdown, 3 yearsBottom 18%
- Beta vs S&P 500 (lower is better)Bottom 37%
- Net debt / EBITDA (lower is better)Top 2%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -79.1% | -15.0% | ↑ |
| Gross margin | 100.0% | 96.4% | ↓ |
| Operating margin | -31.8% | -4.5% | ↑ |
| FCF margin | -107.0% | -65.9% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -15.0% | -79.1% | ↑ | Bottom 17% |
| Gross margin | 96.4% | 100.0% | ↓ | Top 12% |
| Operating margin | -4.5% | -31.8% | ↑ | Top 47% |
| Net margin | 2.9% | -19.5% | ↑ | — |
| Free-cash-flow margin | -65.9% | -107.0% | ↑ | — |
| Return on invested capital | -2.2% | — | Top 35% | |
| Revenue growth, 3-year CAGR | 26.0% | — | Top 25% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- -2.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 32.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 8.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +404.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -29.69×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 19.08%
- Shareholder yield
- 19.08%
- Share count change, 1 year
- -10.0%
- Share count change, 3-year CAGR
- +7.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -4.4%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $14.17
- Target vs current price
- +89.9%
- Analysts with a rating
- 26
- Share rating Buy or Strong Buy
- 73%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +789.6% | +11.7% | +11.5% | +14.1% | — |
| May 12, 2026 | +5.3% | -0.9% | -9.1% | -25.4% | -10.1% |
| Feb 24, 2026 | -100.0% | +0.6% | +8.9% | -16.1% | -30.5% |
| Nov 5, 2025 | +36.0% | +0.3% | +17.5% | +32.8% | +45.0% |
| Aug 6, 2025 | +3.4% | -15.5% | -10.8% | +3.8% | +26.0% |
| May 1, 2025 | +232.6% | -24.8% | -30.7% | -22.0% | -20.9% |
| Feb 11, 2025 | +41.1% | -6.8% | -1.7% | -56.2% | -64.8% |
| Oct 30, 2024 | +22.7% | +0.6% | -2.2% | -11.0% | -34.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | $2.58 | -$0.37 | +789.6% | $249.7M |
| May 12, 2026 | -$0.90 | -$0.95 | +5.3% | $15.6M |
| Feb 24, 2026 | -$1.10 | -$0.55 | -100.0% | $9.5M |
| Nov 5, 2025 | -$0.48 | -$0.75 | +36.0% | $41.9M |
| Aug 6, 2025 | -$0.84 | -$0.87 | +3.4% | $22.4M |
| May 1, 2025 | $1.14 | -$0.86 | +232.6% | $188.8M |
| Feb 11, 2025 | -$0.63 | -$1.07 | +41.1% | $59.2M |
| Oct 30, 2024 | -$0.68 | -$0.88 | +22.7% | $102.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 46.6× | — | — | Top 24% |
| EV / EBITDA | 135.2× | — | — | Top 36% |
| EV / Sales | 1.24× | — | — | Top 14% |
| Free-cash-flow yield | -43.67% | — | — | Bottom 10% |
| Earnings yield | 2.14% | — | — | Top 24% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -0.8%
- 200-day average slope (20 days)
- -4.0%
- Distance from 50-day average
- -13.3%
- Distance from 200-day average
- -26.3%
- RSI (14)
- 33.4
- Relative volume
- 0.70×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 47.1%
- Volatility vs own 5-year history
- 13th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.35
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -46.1%
- Maximum drawdown, 3 years
- -88.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jul 29, 2021 | May 14, 2025 | -94.4% | 952 days | Not yet recovered |
| Jan 19, 2021 | Mar 29, 2021 | -36.3% | 48 days | 81 days (Jul 23, 2021) |
| Oct 13, 2020 | Oct 21, 2020 | -23.6% | 6 days | 31 days (Dec 4, 2020) |
| Dec 15, 2020 | Dec 16, 2020 | -10.5% | 1 days | 4 days (Dec 22, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $478.1M
- P/E (TTM)
- 46.6
- EPS, diluted (TTM)
- $0.16
- Revenue (TTM)
- $316.7M
- 52-week range
- $6.97 – $14.51
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $53.6M | $131.4M | $78.5M | $263.4M | $262.6M |
| Gross profit | $53.6M | $131.4M | $78.5M | $263.4M | $257.4M |
| Operating income | -$188.4M | -$263.2M | -$401.5M | -$250.2M | -$114.9M |
| Net income | -$191.0M | -$282.5M | -$367.3M | -$198.9M | -$80.8M |
| EPS (diluted) | -$3.82 | -$5.31 | -$6.62 | -$2.77 | -$1.28 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102.4M | $59.2M | $188.8M | $22.4M | $41.9M | $9.5M | $15.6M | $249.7M |
| Net income | -$49.2M | -$45.1M | $82.9M | -$61.2M | -$35.1M | -$67.4M | -$57.6M | $169.4M |
| EPS (diluted) | -$0.68 | -$0.63 | $1.14 | -$0.84 | -$0.48 | -$1.04 | -$0.90 | $2.58 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $559.4M | -$273.5M | -$347.8M | -$259.3M | -$273.8M |
| Capital expenditure | -$4.7M | -$6.8M | -$2.9M | -$1.8M | -$1.9M |
| Free cash flow | $554.7M | -$280.3M | -$350.7M | -$261.1M | -$275.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $264.6M | $4.7M | $387.2M | $8.3M | -$91.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $567.9M
- Total assets
- $675.1M
- Total liabilities
- $112.9M
- Total debt
- $8.2M
- Net debt
- -$86.1M
- Shareholders’ equity
- $562.2M
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 4,986,181
- Days to cover
- 5.59
- Change vs previous report
- +5.8%
FINRA short interest, settlement date Sep 15, 2026.